角膜内皮ジストロフィーの世界市場レポート 2025年

角膜内皮ジストロフィー市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で2,528億8,000万米ドルに成長します。この予測期間における成長は、新興国における角膜失明の有病率の増加、アイケアに対する意識の高まり、角膜移植の需要拡大、ヘルスケアインフラの改善、慢性疾患の罹患率の増加などに起因すると考えられます。この期間に予想される主な動向には、再生療法の発展、医療技術の革新、診断技術の改善、眼科用レーザーの技術進歩、高度な眼科ソリューションの開発などがあります。

角膜移植の需要の増加は、角膜内皮ジストロフィー市場の成長を促進すると予想されます。角膜移植は、損傷または病気の角膜を健康なドナー角膜と交換することで、視力を回復させ、目の健康を増進させる外科手術です。この需要の高まりは、角膜疾患の有病率の増加、手術技術の進歩、臓器提供率の向上に起因しています。角膜内皮ジストロフィーは角膜移植によって治療され、損傷した内皮を健康なドナー組織と置き換えることで、角膜の透明性を回復し、浮腫を軽減し、視力を改善します。例えば、米国を拠点とする移植協会であるアイバンク・アソシエーション・オブ・アメリカは2023年、国内の角膜移植術の件数は2.7％増加し、2022年の4万9,597件から2023年には5万925件に増加すると報告しています。その結果、角膜移植の需要の増加が角膜内皮ジストロフィー市場の成長を促進しています。

角膜内皮ジストロフィー市場の主要企業は、アンメット・メディカル・ニーズに対応するため、同種細胞療法などの革新的治療の開発に注力しています。これらの革新的で低侵襲な治療法は、患者の予後を改善することを目的としています。同種細胞療法は、レシピエントを治療するために、遺伝的に異なる同種のドナーの細胞を使用することを含みます。例えば、2024年9月、米国を拠点とする臨床段階のバイオテクノロジー企業であるAurion Biotech Inc.は、角膜内皮疾患である水疱性角膜症の治療薬としてVyznova（ネルテペンドセル）を日本で発表しました。Vyznovaは、角膜内皮細胞に損傷を与え、視力障害を引き起こす水疱性角膜症の治療を目的とした細胞治療薬です。角膜内皮疾患に対する細胞治療としては初めて承認され、日本でも承認されています。Vyznovaは研究室で培養された角膜内皮細胞を利用するため、1人のドナーから最大1,000回分の投与が可能です。この革新的な治療法は、角膜移植に代わる侵襲の少ない治療法であり、ドナー角膜の不足に対処し、角膜疾患患者の視力回復のための新たな解決策を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界角膜内皮ジストロフィーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の角膜内皮ジストロフィー市場：成長率分析
• 世界の角膜内皮ジストロフィー市場の実績：規模と成長, 2019-2024
• 世界の角膜内皮ジストロフィー市場の予測：規模と成長, 2024-2029, 2034F
• 世界角膜内皮ジストロフィー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の角膜内皮ジストロフィー市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 光線療法角膜切除術
• 羊膜移植
• 前部間質穿刺
• 結膜フラップ
• 世界の角膜内皮ジストロフィー市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 先天性遺伝性内皮ジストロフィー1型
• 先天性遺伝性内皮ジストロフィー2
• 後部多形性角膜ジストロフィー
• フックス角膜内皮ジストロフィー
• 世界の角膜内皮ジストロフィー市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 角膜検査とグレーディング
• 角膜断層撮影
• 角膜厚測定
• 角膜細胞数
• 世界の角膜内皮ジストロフィー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の角膜内皮ジストロフィー市場光線療法角膜切除術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エキシマレーザー療法
• 角膜再形成
• 世界の角膜内皮ジストロフィー市場羊膜移植の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 新鮮羊膜移植
• 凍結保存羊膜移植
• 世界の角膜内皮ジストロフィー市場、前部間質穿刺のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手動テクニック
• レーザー支援技術
• 世界の角膜内皮ジストロフィー市場結膜フラップの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 部分皮弁法
• フルフラップテクニック

第7章 地域別・国別分析

• 世界の角膜内皮ジストロフィー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の角膜内皮ジストロフィー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 角膜内皮ジストロフィー市場：競合情勢
• 角膜内皮ジストロフィー市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie（Allergan plc）Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Alcon Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bausch Health+Lomb
• Santen Pharmaceutical Co., Ltd.
• AGC Biologics Inc
• Lumenis Ltd
• Aurion Biotech Inc
• Carl Zeiss Meditec AG
• Keeler Limited
• Kowa Company Ltd.
• ProQR Therapeutics N.V.
• Cellusion Inc.
• OptoTech GmbH
• ActualEyes Inc.
• Arctic Vision Inc.
• Aurion Biotech LLC
• Emmecell S.R.L

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 角膜内皮ジストロフィー市場2029：新たな機会を提供する国
• 角膜内皮ジストロフィー市場2029：新たな機会を提供するセグメント
• 角膜内皮ジストロフィー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Corneal endothelial dystrophy is a genetic eye disorder affecting the cornea's endothelium (inner cell layer), resulting in a gradual loss of corneal clarity. This condition is marked by the degeneration of endothelial cells, which are essential for maintaining the cornea's fluid balance.

The primary treatment options for corneal endothelial dystrophy include phototherapeutic keratectomy (PTK), amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps. PTK is a laser procedure used to remove superficial corneal layers, addressing surface irregularities and scarring. These treatments are applied to various disease types, such as congenital hereditary endothelial dystrophy 1 and 2, posterior polymorphous corneal dystrophy, and Fuchs' endothelial corneal dystrophy. Diagnosis methods include corneal examination and grading, corneal tomography, corneal pachymetry, and corneal cell count. These treatments are utilized by different end-users, including hospitals, clinics, and other healthcare facilities.

The corneal endothelial dystrophy market research report is one of a series of new reports from The Business Research Company that provides corneal endothelial dystrophy market statistics, including the corneal endothelial dystrophy industry global market size, regional shares, competitors with the corneal endothelial dystrophy market share, detailed corneal endothelial dystrophy market segments, market trends, and opportunities, and any further data you may need to thrive in the corneal endothelial dystrophy industry. This corneal endothelial dystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The corneal endothelial dystrophy market size has grown strongly in recent years. It will grow from $170.96 billion in 2024 to $185.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to increasing healthcare expenditures, a rising prevalence of endothelial corneal dystrophy, a growing aging population, a higher incidence of eye diseases, and a surge in corneal disorders.

The corneal endothelial dystrophy market size is expected to see strong growth in the next few years. It will grow to $252.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The projected growth in the forecast period can be attributed to the increasing prevalence of corneal blindness in emerging economies, rising awareness about eye care, growing demand for corneal transplantation, improvements in healthcare infrastructure, and a higher incidence of chronic disorders. Key trends expected during this period include advancements in regenerative therapies, innovations in medical technology, improvements in diagnostic techniques, technological progress in ophthalmic lasers, and the development of advanced ophthalmic solutions.

The increasing demand for corneal transplantation is anticipated to drive the growth of the corneal endothelial dystrophy market. Corneal transplantation is a surgical procedure that replaces a damaged or diseased cornea with a healthy donor cornea to restore vision and enhance eye health. This rising demand is attributed to the growing prevalence of corneal diseases, advancements in surgical techniques, and improved organ donation rates. Corneal endothelial dystrophy is treated through corneal transplantation, which replaces the damaged endothelium with healthy donor tissue, restoring corneal clarity, reducing edema, and improving vision. For example, in 2023, the Eye Bank Association of America, a US-based transplant association, reported a 2.7% increase in domestic keratoplasty procedures, rising from 49,597 in 2022 to 50,925 in 2023. As a result, the increasing demand for corneal transplantation is propelling the growth of the corneal endothelial dystrophy market.

Leading companies in the corneal endothelial dystrophy market are focusing on the development of innovative treatments, such as allogeneic cell therapy, to address unmet medical needs. These innovative, minimally invasive treatment options aim to improve patient outcomes. Allogeneic cell therapy involves using cells from a genetically distinct donor of the same species to treat a recipient. For instance, in September 2024, Aurion Biotech Inc., a US-based clinical-stage biotech company, introduced Vyznova (neltependocel) in Japan for the treatment of bullous keratopathy, a corneal endothelial disease. Vyznova is a cell therapy designed to treat bullous keratopathy, which damages corneal endothelial cells and causes vision impairment. It is the first approved cell therapy for corneal endothelial disease and has received approval in Japan. Vyznova utilizes corneal endothelial cells cultured in a lab, enabling the production of up to 1,000 doses from a single donor. This innovative therapy provides a less invasive alternative to corneal transplants, helping to address the shortage of donor corneas and offering a new solution for restoring vision in patients with corneal diseases.

In February 2024, Eversight, a US-based nonprofit eye bank, collaborated with Emmecell to advance minimally invasive cell therapies for corneal endothelial diseases. This partnership aims to develop treatments for conditions such as corneal edema caused by endothelial cell dysfunction and expand access to innovative therapies worldwide. Emmecell, a US-based biotechnology company, is working on a non-surgical cell therapy to address corneal edema, a condition frequently resulting from corneal endothelial dysfunction.

Major players in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L.

North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in corneal endothelial dystrophy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the corneal endothelial dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The corneal endothelial dystrophy market consists of revenues earned by entities by providing services such as endothelial keratoplasty, specialized contact lenses, and penetrating keratoplasty. The market value includes the value of related goods sold by the service provider or included within the service offering. The corneal endothelial dystrophy market also includes sales of medications, corneal implants, surgical instruments, diagnostic devices, cell therapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Corneal Endothelial Dystrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on corneal endothelial dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for corneal endothelial dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The corneal endothelial dystrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Phototherapeutic Keratectomy; Amniotic Membrane Transplants; Anterior Stromal Puncture; Conjunctival Flaps
• 2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1; Congenital Hereditary Endothelial Dystrophy 2; Posterior Polymorphous Corneal Dystrophy; Fuchs Endothelial Corneal Dystrophy
• 3) By Diagnosis: Cornea Examination And Grading; Corneal Tomography; Corneal Pachymetry; Corneal Cell Count
• 4) By End-User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Phototherapeutic Keratectomy: Excimer Laser Therapy; Corneal Reshaping
• 2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant; Cryopreserved Amniotic Membrane Transplant
• 3) By Anterior Stromal Puncture: Manual Technique; Laser-Assisted Technique
• 4) By Conjunctival Flaps: Partial Flap Technique; Full Flap Technique
• Companies Mentioned: F. Hoffmann-La Roche AG; Abbvie (Allergan plc); Teva Pharmaceutical Industries Ltd; Fujifilm Holdings Corporation; Alcon Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Corneal Endothelial Dystrophy Market Characteristics

3. Corneal Endothelial Dystrophy Market Trends And Strategies

4. Corneal Endothelial Dystrophy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Corneal Endothelial Dystrophy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Corneal Endothelial Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Corneal Endothelial Dystrophy Market Growth Rate Analysis
• 5.4. Global Corneal Endothelial Dystrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Corneal Endothelial Dystrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Corneal Endothelial Dystrophy Total Addressable Market (TAM)

6. Corneal Endothelial Dystrophy Market Segmentation

• 6.1. Global Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phototherapeutic Keratectomy
• Amniotic Membrane Transplants
• Anterior Stromal Puncture
• Conjunctival Flaps
• 6.2. Global Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congenital Hereditary Endothelial Dystrophy 1
• Congenital Hereditary Endothelial Dystrophy 2
• Posterior Polymorphous Corneal Dystrophy
• Fuchs Endothelial Corneal Dystrophy
• 6.3. Global Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cornea Examination And Grading
• Corneal Tomography
• Corneal Pachymetry
• Corneal Cell Count
• 6.4. Global Corneal Endothelial Dystrophy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.5. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Phototherapeutic Keratectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Excimer Laser Therapy
• Corneal Reshaping
• 6.6. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Amniotic Membrane Transplants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fresh Amniotic Membrane Transplant
• Cryopreserved Amniotic Membrane Transplant
• 6.7. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Anterior Stromal Puncture, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Manual Technique
• Laser-Assisted Technique
• 6.8. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Conjunctival Flaps, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Partial Flap Technique
• Full Flap Technique

7. Corneal Endothelial Dystrophy Market Regional And Country Analysis

• 7.1. Global Corneal Endothelial Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Corneal Endothelial Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Corneal Endothelial Dystrophy Market

• 8.1. Asia-Pacific Corneal Endothelial Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Corneal Endothelial Dystrophy Market

• 9.1. China Corneal Endothelial Dystrophy Market Overview
• 9.2. China Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Corneal Endothelial Dystrophy Market

• 10.1. India Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Corneal Endothelial Dystrophy Market

• 11.1. Japan Corneal Endothelial Dystrophy Market Overview
• 11.2. Japan Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Corneal Endothelial Dystrophy Market

• 12.1. Australia Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Corneal Endothelial Dystrophy Market

• 13.1. Indonesia Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Corneal Endothelial Dystrophy Market

• 14.1. South Korea Corneal Endothelial Dystrophy Market Overview
• 14.2. South Korea Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Corneal Endothelial Dystrophy Market

• 15.1. Western Europe Corneal Endothelial Dystrophy Market Overview
• 15.2. Western Europe Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Corneal Endothelial Dystrophy Market

• 16.1. UK Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Corneal Endothelial Dystrophy Market

• 17.1. Germany Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Corneal Endothelial Dystrophy Market

• 18.1. France Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Corneal Endothelial Dystrophy Market

• 19.1. Italy Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Corneal Endothelial Dystrophy Market

• 20.1. Spain Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Corneal Endothelial Dystrophy Market

• 21.1. Eastern Europe Corneal Endothelial Dystrophy Market Overview
• 21.2. Eastern Europe Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Corneal Endothelial Dystrophy Market

• 22.1. Russia Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Corneal Endothelial Dystrophy Market

• 23.1. North America Corneal Endothelial Dystrophy Market Overview
• 23.2. North America Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Corneal Endothelial Dystrophy Market

• 24.1. USA Corneal Endothelial Dystrophy Market Overview
• 24.2. USA Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Corneal Endothelial Dystrophy Market

• 25.1. Canada Corneal Endothelial Dystrophy Market Overview
• 25.2. Canada Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Corneal Endothelial Dystrophy Market

• 26.1. South America Corneal Endothelial Dystrophy Market Overview
• 26.2. South America Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Corneal Endothelial Dystrophy Market

• 27.1. Brazil Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Corneal Endothelial Dystrophy Market

• 28.1. Middle East Corneal Endothelial Dystrophy Market Overview
• 28.2. Middle East Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Corneal Endothelial Dystrophy Market

• 29.1. Africa Corneal Endothelial Dystrophy Market Overview
• 29.2. Africa Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Corneal Endothelial Dystrophy Market Competitive Landscape And Company Profiles

• 30.1. Corneal Endothelial Dystrophy Market Competitive Landscape
• 30.2. Corneal Endothelial Dystrophy Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbvie (Allergan plc) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Alcon Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Corneal Endothelial Dystrophy Market Other Major And Innovative Companies

• 31.1. Bausch Health+Lomb
• 31.2. Santen Pharmaceutical Co., Ltd.
• 31.3. AGC Biologics Inc
• 31.4. Lumenis Ltd
• 31.5. Aurion Biotech Inc
• 31.6. Carl Zeiss Meditec AG
• 31.7. Keeler Limited
• 31.8. Kowa Company Ltd.
• 31.9. ProQR Therapeutics N.V.
• 31.10. Cellusion Inc.
• 31.11. OptoTech GmbH
• 31.12. ActualEyes Inc.
• 31.13. Arctic Vision Inc.
• 31.14. Aurion Biotech LLC
• 31.15. Emmecell S.R.L

32. Global Corneal Endothelial Dystrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Corneal Endothelial Dystrophy Market

34. Recent Developments In The Corneal Endothelial Dystrophy Market

35. Corneal Endothelial Dystrophy Market High Potential Countries, Segments and Strategies

• 35.1 Corneal Endothelial Dystrophy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Corneal Endothelial Dystrophy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Corneal Endothelial Dystrophy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer